ZLAB

Zai Lab Limited ADR

27.00

Sep 03 • 3:59 PM ET +0.52 (1.96%)

26.89

Aftermarket • 6:54 PM ET -0.11 (-0.41%)

Healthcare Biotechnology China Mid NASD

Peers: INCY BMRN IONS ALNY AXSM VRTX NBIX BIIB BABA BIDU

| Held by: IBB CANC SBIO BBP DFEM PGJ FMED DFAE NSI SPGM

Scroll to Statements

Index	-
Market Cap	3.05B
Enterprise Value	2.58B
Income	-188.72M
Sales	450.80M
Book/sh	5.41
Cash/sh	6.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1784
IPO	Sep 20, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	6.76
P/B	4.99
P/C	4.24
P/FCF	-
EV/EBITDA	-
EV/Sales	5.73
Quick Ratio	1.92
Current Ratio	2.13
Debt/Eq	0.42
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.70
EPS next Y	-2.13
EPS next Q	-0.56
EPS this Y	-39.19%
EPS next Y	4.37%
EPS next 5Y	3.57%
EPS past 3/5Y	29.68% 14.26%
Sales past 3/5Y	29.03% 56.57%
EPS Y/Y TTM	17.00%
Sales Y/Y TTM	5.13%
EPS Q/Q	-21.77%
Sales Q/Q	-3.52%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	26.41% 2.35%

Insider Own	7.07%
Insider Trans	-6.27%
Inst Own	34.16%
Inst Trans	-4.33%
ROA	-16.86%
ROE	-26.98%
ROIC	-30.51%
Gross Margin	56.47%
Oper. Margin	-58.74%
Profit Margin	-41.86%
SMA20	4.80%
SMA50	23.31%
SMA200	36.34%
Trades

Shs Outstand	112.24M
Shs Float	104.83M
Short Float	7.12%
Short Ratio	7.43
Short Interest	7.47M
52W High	34.72 -22.24%
52W Low	15.96 69.17%
Volatility	3.38% 4.89%
ATR (14)	1.11
RSI (14)	67.21
Beta	0.72
Rel Volume	0.58
Avg Volume	1.00M
Volume	585,712

Perf Week	0.67%
Perf Month	46.98%
Perf Quarter	55.71%
Perf Half Y	39.90%
Perf YTD	53.06%
Perf Year	-13.74%
Perf 3Y	3.45%
Perf 5Y	-81.45%
Perf 10Y	-
Recom	1.36
Target Price	33.00
Prev Close	26.48
Price	27.00
Change %	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-25	Resumed	Jefferies	Buy	$52
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Mar-03-25	Downgrade	BofA Securities	Buy → Neutral	$29 → $36.10
Dec-14-23	Initiated	Morgan Stanley	Overweight	$47.50
Aug-10-23	Initiated	Cantor Fitzgerald	Overweight	$70
Jan-21-22	Initiated	Macquarie	Outperform	$64
Oct-12-21	Initiated	Bernstein	Mkt Perform
Apr-28-20	Initiated	Goldman	Buy
Apr-15-20	Initiated	Guggenheim	Buy	$75
Jul-12-19	Initiated	BofA/Merrill	Buy
Jul-05-19	Initiated	Macquarie	Outperform
Jan-29-19	Initiated	Credit Suisse	Outperform
Nov-21-18	Initiated	Jefferies	Buy
Jun-21-18	Resumed	Leerink Partners	Outperform	$43
Feb-14-18	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Initiated	Leerink Partners	Outperform	$42
Oct-16-17	Initiated	JP Morgan	Neutral	$32

Show Previous Ratings

Aug-17-26 06:00AM	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis (Business Wire)
Aug-06-26 03:03PM	Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ... (GuruFocus.com) +13.66%
06:30AM	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
Aug-03-26 07:00AM	U.S. FDA Grants Orphan Drug Designation to Zai Labs DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) (Business Wire)
Jul-22-26 07:30AM	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 (Business Wire)
07:00AM	Loading…
Jun-16-26 07:00AM	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas (Business Wire)
Jun-08-26 08:34PM	Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
May-21-26 06:09PM	Zai Lab Announces Changes to Senior Leadership Team (Business Wire)
May-11-26 07:00AM	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) (Business Wire) +5.32%
May-07-26 06:00AM	Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire) -5.93%
Apr-22-26 07:30AM	Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 (Business Wire) -6.42%
Apr-18-26 09:00AM	Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31R Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases (Business Wire)
Apr-17-26 03:01PM	Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas (Business Wire)
Apr-16-26 05:10AM	Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study (Pharmaceutical Business Review)
Apr-01-26 07:30AM	Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy (Business Wire) +8.13%
04:35PM	Loading…
Mar-17-26 04:35PM	Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) (Business Wire)
Feb-27-26 06:17PM	Zai Lab Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:12PM	Zai Lab Ltd (ZLAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:00AM	Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:00AM	Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates (Business Wire)
Feb-10-26 08:30AM	Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 (Business Wire) +6.02%
Feb-06-26 08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily) +6.01%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire)
Jan-30-26 02:07AM	UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform (Insider Monkey)
Jan-13-26 08:00AM	Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-09-26 03:16AM	UBS Gives Zai Lab (ZLAB) a Buy Rating (Insider Monkey)
Jan-07-26 05:38AM	Zai Lab's Augtyro receives NMPA approval for solid tumours in China (Pharmaceutical Business Review)
Jan-06-26 07:30AM	Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors (Business Wire)
Jan-05-26 07:30AM	Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-23-25 07:30AM	Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia (Business Wire)
07:00AM	Loading…
Dec-08-25 07:00AM	Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis (Business Wire)
Dec-07-25 12:11AM	Zai Lab Announces Updates to Chinas National Reimbursement Drug List (Business Wire)
Nov-30-25 05:41AM	Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum (Insider Monkey)
Nov-06-25 02:08PM	Zai Lab Ltd (ZLAB) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) -6.65%
07:00AM	Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
Oct-31-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in November and December 2025 (Business Wire)
Oct-24-25 09:00AM	Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study (Business Wire) -6.07%
Oct-15-25 07:30AM	Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 (Business Wire)
Oct-13-25 12:02PM	Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference (Business Wire)
Sep-16-25 12:32PM	Zai Lab Limited (ZLAB): A Bull Case Theory (Insider Monkey)
Sep-10-25 04:01PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily) -9.81% +14.37%
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-28-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in September 2025 (Business Wire)
Aug-19-25 07:30AM	Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer (Business Wire)
Aug-13-25 11:00AM	Zai Lab Establishes Oncology Scientific Advisory Board (Business Wire)
Aug-07-25 09:30AM	Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings (Zacks) -11.98%
06:00AM	Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
Aug-06-25 01:05PM	This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom (Investor's Business Daily)
Jul-24-25 11:47PM	Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment (Insider Monkey)
Jul-23-25 09:57AM	Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar? (Zacks)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire)
Jul-10-25 07:30AM	Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 (Business Wire)
Jun-30-25 09:05AM	Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer (Business Wire)
Jun-13-25 07:00AM	Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 (Business Wire)
Jun-02-25 07:00AM	Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting (Business Wire)
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-30-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in June 2025 (Business Wire)
May-20-25 06:08AM	FDA grants fast track status to Zai Lab's lung cancer treatment (Pharmaceutical Business Review)
May-19-25 07:00AM	Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer (Business Wire) +6.66%
May-09-25 03:11AM	Zai Lab Ltd (ZLAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-08-25 10:00AM	Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
May-07-25 11:17AM	Zai Lab Q1 2025 Earnings Preview (Seeking Alpha)
May-05-25 05:58PM	Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey) -5.07%
Apr-28-25 08:09AM	Baron Emerging Markets Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 01:12PM	Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 (Business Wire) -5.33%
Apr-23-25 10:56AM	Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting (Business Wire)
Apr-21-25 07:30AM	Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors (Business Wire)
Apr-17-25 05:00AM	Bulls In A China Shop: 5 Chinese Stocks To Ride Out The Trade War (Seeking Alpha)
Apr-15-25 12:00PM	All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy (Zacks)
Apr-14-25 09:10AM	Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? (Zacks) +6.70%
07:30AM	Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025 (Business Wire)
Apr-10-25 01:39PM	Zai Lab Limited (ZLAB): Among Stocks Insiders Sold in April After Trump's Tariff Rollout (Insider Monkey) -10.13%
Mar-26-25 07:00AM	Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha) -6.00%
Mar-20-25 01:05PM	Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks (SeekingAlpha)
Mar-14-25 10:40AM	Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025? (Insider Monkey) +5.70%
Mar-13-25 08:35PM	Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer (TipRanks)
Mar-12-25 07:30PM	Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
Mar-04-25 09:55AM	Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet (Zacks) +7.15%
Mar-03-25 07:30AM	Zai Lab Announces Participation in Investor Conferences in March 2025 (Business Wire) -8.40%
Feb-28-25 02:09AM	Zai Lab Ltd (ZLAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Path to Profitability (GuruFocus.com)
Feb-27-25 12:43PM	China Biotech's Sales Jump 66% But Bottom Line Misses Views (Investor's Business Daily)
06:00AM	Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates (Business Wire)
Feb-26-25 11:59AM	Is Zai Lab Limited (ZLAB) the Best Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-24-25 10:25AM	Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Jan-28-25 09:55AM	Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade (Zacks)
07:30AM	Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025 (Business Wire)
Jan-23-25 10:14AM	FDA grants ODD status to Zai Labs lung cancer treatment (Pharmaceutical Technology)
01:41AM	Why Is Andreas Halvorsen Bullish On Zai Lab Limited (ZLAB) Now? (Insider Monkey)
Jan-22-25 11:15PM	Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) (Business Wire)
Jan-20-25 07:06PM	Heres Why Analysts Are Bullish on Zai Lab Limited (ZLAB) (Insider Monkey)
Jan-17-25 07:30AM	Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia (Business Wire)
Jan-15-25 03:58PM	Zai Labs announces positive results in China arm of Phase III cervical cancer trial (Clinical Trials Arena)
07:30AM	Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer (Business Wire)
Jan-11-25 07:41AM	Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement (TipRanks)
Jan-10-25 07:30AM	Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (Business Wire)
07:30AM	Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore (Business Wire)
Jan-09-25 06:30PM	Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate (Business Wire)
Dec-24-24 12:00PM	Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

FounderDr. Ying Du Ph.D.

President and Head of Global Research & DevelopmentDr. Rafael G. Amado M.D.

Chief Financial OfficerDr. Yajing Chen Ph.D.

J.D.Mr. Frazor Titus Edmondson III

Senior VP & Head of Investor RelationsMs. Christine Chiou

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chen Yajing	Chief Financial Officer	Aug 19 '26	Sale	27.00	260	7,020	35,635	Aug 21 04:16 PM
Smiley Joshua L	Former Officer	Aug 20 '26	Proposed Sale	26.18	98,653	2,582,511		Aug 20 04:20 PM
Chen Yajing	Officer	Aug 19 '26	Proposed Sale	27.00	260	7,020		Aug 19 01:51 PM
Lis William	Director	Aug 12 '26	Sale	25.00	8,506	212,650	41,931	Aug 13 04:15 PM
Chen Yajing	Chief Financial Officer	Aug 11 '26	Sale	25.00	619	15,475	35,072	Aug 13 04:15 PM
Lis William	Director	Aug 12 '26	Proposed Sale	25.00	8,506	212,650		Aug 12 10:42 AM
Chen Yajing	Officer	Aug 11 '26	Proposed Sale	25.00	619	15,475		Aug 11 04:22 PM
GAYNOR RICHARD	Director	Jul 01 '26	Buy	19.05	1,736	33,071	80,737	Jul 06 04:14 PM
Du Ying	Chairperson & CEO	Jun 30 '26	Sale	18.53	7,026	130,220	1,203,784	Jul 01 04:24 PM
Du Ying	Officer	Jun 30 '26	Proposed Sale	18.53	7,026	130,220		Jun 30 03:13 PM
Edmondson Frazor Titus III	Chief Legal Officer	Jun 26 '26	Sale	17.46	4,103	71,642	30,346	Jun 29 04:18 PM
Du Ying	Chairperson & CEO	Jun 26 '26	Sale	17.46	24,543	428,545	1,192,840	Jun 29 04:17 PM
Chen Yajing	Chief Financial Officer	Jun 26 '26	Sale	17.46	2,264	39,532	35,691	Jun 29 04:17 PM
Chen Yajing	Officer	Jun 26 '26	Proposed Sale	17.46	2,264	39,532		Jun 26 03:38 PM
Edmondson Frazor Titus III	Officer	Jun 26 '26	Proposed Sale	17.46	4,103	71,644		Jun 26 03:18 PM
Du Ying	Officer	Jun 26 '26	Proposed Sale	17.46	24,543	428,553		Jun 26 03:12 PM
Lis William	Director	Jun 22 '26	Sale	18.09	7,040	127,354	50,437	Jun 24 04:05 PM
Lis William	Director	Jun 22 '26	Proposed Sale	18.09	7,040	127,354		Jun 22 10:10 AM
Du Ying	Chairperson & CEO	May 19 '26	Option Exercise	1.74	261,092	454,300	1,383,718	May 21 04:19 PM
Du Ying	Chairperson & CEO	May 15 '26	Option Exercise	1.74	50,000	87,000	1,172,626	May 19 04:18 PM
Du Ying	Chairperson & CEO	May 18 '26	Option Exercise	1.74	50,000	87,000	1,172,626	May 19 04:18 PM
Du Ying	Chairperson & CEO	May 15 '26	Sale	20.74	50,000	1,037,110	1,122,626	May 19 04:18 PM
Du Ying	Chairperson & CEO	May 18 '26	Sale	19.00	50,000	949,765	1,122,626	May 19 04:18 PM
Du Ying	Officer	May 18 '26	Proposed Sale	19.52	50,000	976,000		May 18 11:34 AM
Edmondson Frazor Titus III	Chief Legal Officer	May 14 '26	Sale	20.19	3,517	71,008	19,849	May 15 04:46 PM
Du Ying	Chairperson & CEO	May 13 '26	Option Exercise	1.74	50,000	87,000	1,172,626	May 15 04:45 PM
Du Ying	Chairperson & CEO	May 14 '26	Option Exercise	1.74	50,000	87,000	1,172,626	May 15 04:45 PM
Du Ying	Chairperson & CEO	May 14 '26	Sale	20.09	50,000	1,004,575	1,122,626	May 15 04:45 PM
Du Ying	Chairperson & CEO	May 13 '26	Sale	19.97	50,000	998,469	1,122,626	May 15 04:45 PM
Du Ying	Officer	May 15 '26	Proposed Sale	20.46	50,000	1,023,000		May 15 09:49 AM
Du Ying	Officer	May 14 '26	Proposed Sale	20.09	50,000	1,004,578		May 14 04:17 PM
Edmondson Frazor Titus III	Officer	May 14 '26	Proposed Sale	20.19	3,517	71,008		May 14 09:50 AM
Du Ying	Officer	May 13 '26	Proposed Sale	19.20	50,000	960,000		May 13 02:06 PM
Smiley Joshua L	See Remarks	Apr 06 '26	Sale	20.45	3,017	61,692	117,602	Apr 08 07:35 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 06 '26	Sale	20.45	1,224	25,028	23,366	Apr 08 07:34 PM
Du Ying	Chairperson & CEO	Apr 06 '26	Sale	20.45	2,653	54,249	1,122,626	Apr 08 07:34 PM
Chen Yajing	Chief Financial Officer	Apr 06 '26	Sale	20.45	853	17,442	31,705	Apr 08 07:33 PM
Amado Rafael	See Remarks	Apr 06 '26	Sale	20.45	2,739	56,007	57,022	Apr 08 07:33 PM
Smiley Joshua L	Officer	Apr 06 '26	Proposed Sale	20.45	3,017	61,693		Apr 06 03:26 PM
Du Ying	Officer	Apr 06 '26	Proposed Sale	20.45	2,653	54,250		Apr 06 03:21 PM
Edmondson Frazor Titus III	Officer	Apr 06 '26	Proposed Sale	20.45	1,224	25,029		Apr 06 03:15 PM
Amado Rafael	Officer	Apr 06 '26	Proposed Sale	20.45	2,739	56,008		Apr 06 03:11 PM
Chen Yajing	Officer	Apr 06 '26	Proposed Sale	20.45	853	17,443		Apr 06 03:04 PM
Smiley Joshua L	See Remarks	Apr 02 '26	Sale	20.39	9,614	196,029	120,619	Apr 03 05:59 PM
Edmondson Frazor Titus III	Chief Legal Officer	Apr 02 '26	Sale	20.39	4,194	85,516	24,590	Apr 03 05:58 PM
Du Ying	Chairperson & CEO	Apr 02 '26	Sale	20.39	5,576	113,695	1,125,279	Apr 03 05:58 PM
Chen Yajing	Chief Financial Officer	Apr 02 '26	Sale	20.39	5,199	106,008	32,558	Apr 03 05:57 PM
Amado Rafael	See Remarks	Apr 02 '26	Sale	20.39	9,910	202,065	59,761	Apr 03 05:57 PM
Amado Rafael	Officer	Apr 02 '26	Proposed Sale	20.39	9,910	202,066		Apr 02 04:59 PM
Du Ying	Officer	Apr 02 '26	Proposed Sale	20.39	5,576	113,695		Apr 02 04:56 PM
Smiley Joshua L	Officer	Apr 02 '26	Proposed Sale	20.39	9,614	196,030		Apr 02 04:40 PM
Edmondson Frazor Titus III	Officer	Apr 02 '26	Proposed Sale	20.39	4,194	85,516		Apr 02 04:28 PM
Chen Yajing	Officer	Apr 02 '26	Proposed Sale	20.39	5,199	106,008		Apr 02 04:20 PM
GAYNOR RICHARD	Director	Mar 17 '26	Buy	18.91	1,731	32,733	56,630	Mar 19 04:05 PM
Smiley Joshua L	See Remarks	Mar 13 '26	Sale	18.63	1,966	36,623	91,026	Mar 16 04:09 PM
Edmondson Frazor Titus III	Chief Legal Officer	Mar 13 '26	Sale	18.63	1,281	23,862	6,494	Mar 16 04:08 PM
Chen Yajing	Chief Financial Officer	Mar 13 '26	Sale	18.63	1,703	31,723	19,999	Mar 16 04:08 PM
Amado Rafael	See Remarks	Mar 13 '26	Sale	18.63	2,957	55,083	44,757	Mar 16 04:07 PM
Edmondson Frazor Titus III	Officer	Mar 13 '26	Proposed Sale	18.63	1,281	23,863		Mar 13 04:04 PM
Smiley Joshua L	Officer	Mar 13 '26	Proposed Sale	18.63	1,966	36,623		Mar 13 03:50 PM
Amado Rafael	Officer	Mar 13 '26	Proposed Sale	18.63	2,957	55,084		Mar 13 03:49 PM
Chen Yajing	Officer	Mar 13 '26	Proposed Sale	18.63	1,703	31,724		Mar 13 03:21 PM
Du Ying	Chairperson & CEO	Mar 10 '26	Option Exercise	1.74	261,092	454,300	1,225,253	Mar 12 04:12 PM
Du Ying	Chairperson & CEO	Mar 11 '26	Sale	19.08	1,067	20,363	1,109,905	Mar 12 04:12 PM
Du Ying	Officer	Mar 11 '26	Proposed Sale	19.08	1,067	20,362		Mar 11 03:21 PM
Du Ying	Chairperson & CEO	Mar 06 '26	Option Exercise	1.74	50,000	87,000	1,014,161	Mar 10 04:08 PM
Du Ying	Chairperson & CEO	Mar 09 '26	Option Exercise	1.74	50,000	87,000	1,014,161	Mar 10 04:08 PM
Du Ying	Chairperson & CEO	Mar 06 '26	Sale	19.42	50,000	970,935	964,161	Mar 10 04:08 PM
Du Ying	Chairperson & CEO	Mar 09 '26	Sale	19.03	50,000	951,465	964,161	Mar 10 04:08 PM
Du Ying	Officer	Mar 09 '26	Proposed Sale	19.21	50,000	960,500		Mar 09 02:12 PM
Edmondson Frazor Titus III	Chief Legal Officer	Mar 05 '26	Sale	19.06	15,569	296,745	3,517	Mar 06 04:26 PM
Du Ying	Chairperson & CEO	Mar 04 '26	Option Exercise	1.74	50,000	87,000	1,014,161	Mar 06 04:25 PM
Du Ying	Chairperson & CEO	Mar 05 '26	Option Exercise	1.74	50,000	87,000	1,014,161	Mar 06 04:25 PM
Du Ying	Chairperson & CEO	Mar 05 '26	Sale	19.22	50,000	961,055	964,161	Mar 06 04:25 PM
Du Ying	Chairperson & CEO	Mar 04 '26	Sale	19.16	50,000	958,153	964,161	Mar 06 04:25 PM
Du Ying	Officer	Mar 06 '26	Proposed Sale	19.18	50,000	959,000		Mar 06 10:57 AM
Amado Rafael	See Remarks	Mar 03 '26	Sale	17.38	10,000	173,800	42,391	Mar 05 04:07 PM
Edmondson Frazor Titus III	Officer	Mar 05 '26	Proposed Sale	19.06	15,569	296,745		Mar 05 01:20 PM
Du Ying	Officer	Mar 05 '26	Proposed Sale	19.06	50,000	953,000		Mar 05 01:12 PM
Du Ying	Officer	Mar 04 '26	Proposed Sale	18.28	50,000	914,000		Mar 04 11:21 AM
Amado Rafael	Officer	Mar 03 '26	Proposed Sale	17.38	10,000	173,800		Mar 03 12:38 PM
Amado Rafael	See Remarks	Dec 31 '25	Sale	17.43	10,787	188,039	52,391	Jan 02 04:15 PM
Amado Rafael	Officer	Dec 31 '25	Proposed Sale	17.43	10,787	188,034		Dec 31 03:29 PM
Edmondson Frazor Titus III	Chief Legal Officer	Dec 16 '25	Sale	17.14	8,651	148,278	19,086	Dec 18 04:34 PM
Edmondson Frazor Titus III	Officer	Dec 16 '25	Proposed Sale	17.14	8,651	148,278		Dec 16 10:47 AM
Edmondson Frazor Titus III	Chief Legal Officer	Nov 21 '25	Sale	19.78	14,328	283,408	27,737	Nov 25 04:11 PM
Edmondson Frazor Titus III	Officer	Nov 21 '25	Proposed Sale	19.78	14,328	283,408		Nov 21 09:43 AM
Chen Yajing	Chief Financial Officer	Nov 03 '25	Sale	26.83	240	6,439	17,444	Nov 04 04:13 PM
Chen Yajing	Officer	Nov 03 '25	Proposed Sale	26.83	240	6,439		Nov 03 03:31 PM
Chen Yajing	Chief Financial Officer	Oct 02 '25	Sale	34.25	456	15,617	17,184	Oct 03 04:20 PM
Chen Yajing	Officer	Oct 02 '25	Proposed Sale	34.25	456	15,617		Oct 02 03:36 PM
Smiley Joshua L	See Remarks	Sep 10 '25	Buy	28.91	10,000	289,100	86,604	Sep 12 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZLAB

Zai Lab Limited ADR

Upgrade your Finviz experience